LivaNova Balance Sheet Health
Financial Health criteria checks 3/6
LivaNova has a total shareholder equity of $1.3B and total debt of $586.7M, which brings its debt-to-equity ratio to 45.9%. Its total assets and total liabilities are $2.4B and $1.2B respectively. LivaNova's EBIT is $66.4M making its interest coverage ratio 1.9. It has cash and short-term investments of $266.5M.
Key information
45.9%
Debt to equity ratio
US$586.65m
Debt
Interest coverage ratio | 1.9x |
Cash | US$266.50m |
Equity | US$1.28b |
Total liabilities | US$1.15b |
Total assets | US$2.43b |
Recent financial health updates
Recent updates
Is It Time To Consider Buying LivaNova PLC (NASDAQ:LIVN)?
Feb 05A Look At The Intrinsic Value Of LivaNova PLC (NASDAQ:LIVN)
Jan 15LivaNova PLC's (NASDAQ:LIVN) Business And Shares Still Trailing The Industry
Dec 25LivaNova (NASDAQ:LIVN) Could Be At Risk Of Shrinking As A Company
Nov 29We Think LivaNova's (NASDAQ:LIVN) Profit Is Only A Baseline For What They Can Achieve
Nov 08At US$47.94, Is LivaNova PLC (NASDAQ:LIVN) Worth Looking At Closely?
Oct 16Are Investors Undervaluing LivaNova PLC (NASDAQ:LIVN) By 44%?
Sep 25Capital Allocation Trends At LivaNova (NASDAQ:LIVN) Aren't Ideal
Jul 26Should You Investigate LivaNova PLC (NASDAQ:LIVN) At US$51.43?
Jul 03An Intrinsic Calculation For LivaNova PLC (NASDAQ:LIVN) Suggests It's 37% Undervalued
Jun 09Investors Could Be Concerned With LivaNova's (NASDAQ:LIVN) Returns On Capital
Apr 13What Does LivaNova PLC's (NASDAQ:LIVN) Share Price Indicate?
Mar 13Estimating The Fair Value Of LivaNova PLC (NASDAQ:LIVN)
Feb 15Returns At LivaNova (NASDAQ:LIVN) Are On The Way Up
Nov 25Is There Now An Opportunity In LivaNova PLC (NASDAQ:LIVN)?
Oct 29LivaNova Loses Profit Momentum On Higher R&D Expense
Oct 13LivaNova PLC (NASDAQ:LIVN) Shares Could Be 30% Below Their Intrinsic Value Estimate
Oct 11FDA labels recall of blood bypass pump systems by LivaNova as most serious
Sep 30Returns On Capital At LivaNova (NASDAQ:LIVN) Have Hit The Brakes
Aug 09LivaNova PLC Non-GAAP EPS of $0.53 beats by $0.01, revenue of $254.2M beats by $4.65M, lowers FY earning guidance
Aug 03Is There Now An Opportunity In LivaNova PLC (NASDAQ:LIVN)?
Jul 19A Look At The Fair Value Of LivaNova PLC (NASDAQ:LIVN)
Jun 27LivaNova Matures Into Profitability, Still Waiting On DTD
May 10Capital Allocation Trends At LivaNova (NASDAQ:LIVN) Aren't Ideal
Apr 05LivaNova Continues To Be A Spring-Loaded Opportunity In Neuromodulation
Feb 11Is LivaNova PLC (NASDAQ:LIVN) Trading At A 35% Discount?
Jan 30At US$87.75, Is LivaNova PLC (NASDAQ:LIVN) Worth Looking At Closely?
Dec 29Does LivaNova (NASDAQ:LIVN) Have A Healthy Balance Sheet?
Nov 29Milan Court Decision Does Not Change LivaNova Bullish Story
Nov 16LivaNova's Peculiar Situation Makes For A Cheap Option
Aug 23Financial Position Analysis
Short Term Liabilities: LIVN's short term assets ($988.2M) exceed its short term liabilities ($335.0M).
Long Term Liabilities: LIVN's short term assets ($988.2M) exceed its long term liabilities ($817.0M).
Debt to Equity History and Analysis
Debt Level: LIVN's net debt to equity ratio (25.1%) is considered satisfactory.
Reducing Debt: LIVN's debt to equity ratio has increased from 11.3% to 45.9% over the past 5 years.
Debt Coverage: LIVN's debt is not well covered by operating cash flow (12.8%).
Interest Coverage: LIVN's interest payments on its debt are not well covered by EBIT (1.9x coverage).